174 related articles for article (PubMed ID: 37753554)
1. Selective multimodal bladder-sparing therapy for muscle-invasive bladder cancer: the present and the future.
Koga F
Expert Rev Anticancer Ther; 2023; 23(11):1127-1139. PubMed ID: 37753554
[TBL] [Abstract][Full Text] [Related]
2. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review.
Ploussard G; Daneshmand S; Efstathiou JA; Herr HW; James ND; Rödel CM; Shariat SF; Shipley WU; Sternberg CN; Thalmann GN; Kassouf W
Eur Urol; 2014 Jul; 66(1):120-37. PubMed ID: 24613684
[TBL] [Abstract][Full Text] [Related]
3. [Bladder-sparing trimodal therapy for muscle invasive bladder cancer].
Khalifa J; Roumiguié M; Pouessel D; Sargos P
Cancer Radiother; 2022 Oct; 26(6-7):771-778. PubMed ID: 35970682
[TBL] [Abstract][Full Text] [Related]
4. Bladder sparing surgery in high-grade bladder cancer.
Yakovlev PG; Klyushin DA; Vereshchako RI
Exp Oncol; 2019 Jun; 41(2):160-165. PubMed ID: 31262149
[TBL] [Abstract][Full Text] [Related]
5. Bladder-sparing treatment options in localized muscle-invasive bladder cancer.
Nason GJ; Ajib K; Tan GH; Kulkarni GS
Expert Rev Anticancer Ther; 2020 Mar; 20(3):179-188. PubMed ID: 32129122
[No Abstract] [Full Text] [Related]
6. Bladder preservation therapy for muscle invasive bladder cancer: the past, present and future.
Kimura T; Ishikawa H; Kojima T; Kandori S; Kawahara T; Sekino Y; Sakurai H; Nishiyama H
Jpn J Clin Oncol; 2020 Sep; 50(10):1097-1107. PubMed ID: 32895714
[TBL] [Abstract][Full Text] [Related]
7. Is trimodal therapy the current standard for muscle-invasive bladder cancer?
López Valcárcel M; Barrado Los Arcos M; Ferri Molina M; Cienfuegos Belmonte I; Duque Santana V; Gajate Borau P; Fernández Ibiza J; Álvarez Maestro M; Sargos P; López Campos F; Couñago F
Actas Urol Esp (Engl Ed); 2024 Jun; 48(5):345-355. PubMed ID: 38575067
[TBL] [Abstract][Full Text] [Related]
8. Contemporary and Emerging Approaches to Bladder-Preserving Trimodality Therapy for Muscle-Invasive Bladder Cancer.
Konieczkowski DJ; Efstathiou JA; Mouw KW
Hematol Oncol Clin North Am; 2021 Jun; 35(3):567-584. PubMed ID: 33958151
[TBL] [Abstract][Full Text] [Related]
9. The efficacy of trimodal chemoradiotherapy with gemcitabine and cisplatin as a bladder-preserving strategy for the treatment of muscle-invasive bladder cancer: a single-arm phase II study.
Kobayashi K; Matsumoto H; Misumi T; Ito H; Hirata H; Nagao K; Matsuyama H
Jpn J Clin Oncol; 2022 Oct; 52(10):1201-1207. PubMed ID: 35675636
[TBL] [Abstract][Full Text] [Related]
10. Trimodal therapy in muscle invasive bladder cancer management.
Polo-Alonso E; Kuk C; Guruli G; Paul AK; Thalmann G; Kamat A; Solsona E; Thalmann G; Urdaneta AI; Zlotta AR; Mir MC
Minerva Urol Nefrol; 2020 Dec; 72(6):650-662. PubMed ID: 33263367
[TBL] [Abstract][Full Text] [Related]
11. Trimodal therapy for muscle-invasive bladder cancer.
Mathes J; Rausch S; Todenhöfer T; Stenzl A
Expert Rev Anticancer Ther; 2018 Dec; 18(12):1219-1229. PubMed ID: 30324833
[TBL] [Abstract][Full Text] [Related]
12. Can bladder preservation therapy come to the center stage?
Inamoto T; Ibuki N; Komura K; Juri H; Yamamoto K; Yamamoto K; Fujita K; Nonomura N; Narumi Y; Azuma H
Int J Urol; 2018 Feb; 25(2):134-140. PubMed ID: 29171098
[TBL] [Abstract][Full Text] [Related]
13. Comparing Survival Outcomes and Costs Associated With Radical Cystectomy and Trimodal Therapy for Older Adults With Muscle-Invasive Bladder Cancer.
Williams SB; Shan Y; Jazzar U; Mehta HB; Baillargeon JG; Huo J; Senagore AJ; Orihuela E; Tyler DS; Swanson TA; Kamat AM
JAMA Surg; 2018 Oct; 153(10):881-889. PubMed ID: 29955780
[TBL] [Abstract][Full Text] [Related]
14. Selective tetramodal bladder-preservation therapy, incorporating induction chemoradiotherapy and consolidative partial cystectomy with pelvic lymph node dissection for muscle-invasive bladder cancer: oncological and functional outcomes of 107 patients.
Kijima T; Tanaka H; Koga F; Masuda H; Yoshida S; Yokoyama M; Ishioka J; Matsuoka Y; Saito K; Kihara K; Fujii Y
BJU Int; 2019 Aug; 124(2):242-250. PubMed ID: 30811784
[TBL] [Abstract][Full Text] [Related]
15. Selective bladder preservation with curative intent for muscle-invasive bladder cancer: a contemporary review.
Koga F; Kihara K
Int J Urol; 2012 May; 19(5):388-401. PubMed ID: 22409269
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant Chemotherapy-Guided Bladder-Sparing Treatment for Muscle-Invasive Bladder Cancer: Results of a Pilot Phase II Study.
Shi H; Zhang W; Bi X; Wang D; Xiao Z; Guan Y; Guan K; Tian J; Bai H; Hu L; Cao C; Jiang W; Hu Z; Zhang J; Chen Y; Zheng S; Feng X; Li C; Li Y; Ma J; Liu Y; Zhou A; Shou J
Cancer Res Treat; 2021 Oct; 53(4):1156-1165. PubMed ID: 33592141
[TBL] [Abstract][Full Text] [Related]
17. Bladder-sparing strategies in patients with clinically localized muscle-invasive bladder cancer.
de Angelis M; Basile G; Scornajenghi CM; Asero V; Del Giudice F; Moschini M
Curr Opin Urol; 2023 Sep; 33(5):354-359. PubMed ID: 37395512
[TBL] [Abstract][Full Text] [Related]
18. Bladder Preservation Therapy: Review of Literature and Future Directions of Trimodal Therapy.
El-Achkar A; Souhami L; Kassouf W
Curr Urol Rep; 2018 Nov; 19(12):108. PubMed ID: 30392150
[TBL] [Abstract][Full Text] [Related]
19. Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic.
Kulkarni GS; Hermanns T; Wei Y; Bhindi B; Satkunasivam R; Athanasopoulos P; Bostrom PJ; Kuk C; Li K; Templeton AJ; Sridhar SS; van der Kwast TH; Chung P; Bristow RG; Milosevic M; Warde P; Fleshner NE; Jewett MAS; Bashir S; Zlotta AR
J Clin Oncol; 2017 Jul; 35(20):2299-2305. PubMed ID: 28410011
[TBL] [Abstract][Full Text] [Related]
20. Bladder Sparing Approaches for Muscle-Invasive Bladder Cancers.
El-Taji OM; Alam S; Hussain SA
Curr Treat Options Oncol; 2016 Mar; 17(3):15. PubMed ID: 26942590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]